Search / Trial NCT06226194

Genetic Susceptibility to Predict Weight Loss After Bariatric Surgery

Launched by INSTITUT DE RECERCA BIOMÈDICA DE LLEIDA · Jan 17, 2024

Trial Information

Current as of October 08, 2024

Recruiting

Keywords

Description

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • * Men and women between the ages of 18 and 65 at the time of surgery
  • * SG or RYBP as bariatric procedure.
  • * With a BMI≥35.0 kg/m2 with one or more comorbidities or a BMI\>40.0 kg/m2 at the time of surgery.
  • * Provision of an informed consent form signed and personally dated by the patient.
  • * With available baseline data (anthropometric, analytical, surgical procedure, pharmacological therapies, and obesity-related comorbidities).
  • Exclusion Criteria:
  • * Any previous gastrointestinal surgery
  • * Treatment with any approved antiobesity drug in Spain (orlistat, liraglutide 3.0 mg and/or naltrexone/bupropion extended release) or systemic glucocorticoids for more than 4 consecutive weeks during the 3 years following BS
  • * End stage kidney disease (eGFR \<15 ml/min/1.73m2) or liver cirrhosis at baseline
  • * Patients who developed any major medical conditions that limits the practice of a healthy life within normal limits (advanced cardiovascular disease or heart failure, stroke with neurological sequelae, chronic pulmonary obstructive disease with dyspnea at minimal exertion, severe joint pathology, end stage renal failure, or active cancer)
  • * Known type 1 diabetes or LADA diabetes
  • * Women who become pregnant during the follow-up period
  • * Current drug or alcohol abuse
  • * Uncontrolled psychiatric illness or eating disorders developed during the follow-up period.

About Institut De Recerca Biomèdica De Lleida

The Institut de Recerca Biomèdica de Lleida (IRBLleida) is a leading biomedical research institute dedicated to advancing scientific knowledge and improving healthcare outcomes through innovative research. Located in Lleida, Spain, the institute focuses on translational medicine, bridging laboratory discoveries with clinical applications. IRBLleida fosters collaboration among researchers, healthcare professionals, and industry partners, emphasizing a multidisciplinary approach to tackle pressing health challenges. With a commitment to excellence in research and a strong emphasis on patient-centered outcomes, IRBLleida plays a pivotal role in driving advancements in biomedical science and enhancing the quality of life within the community.

Locations

Lleida, Leida, Spain

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0